Mary Alpaugh

Associate Professor

    • 1484 Citations
    • 17 h-Index

    Research output per year

    If you made any changes in Pure these will be visible here soon.

    Personal profile

    Research interests

    Research Expertise:
    Cancer Biology | Tumor Progression | Metastasis | Intravasation

    My research focuses predominantly on the molecular mechanisms of intravasation, the rate-limiting step of metastasis, and resistance/susceptibility of lymphovascular emboli to therapeutics.

    Metastasis poses the single most difficult clinical challenge in the attempt to manage and treat cancer. In this effort, I have established patient-derived xenografts, signifcantly the first (and only) human transplantable inflammatory breast cancer xenograft, called MARY-X. Inflammatory breast cancer (IBC) is one of the most aggressive types of breast cancer; nearly 100% of all women with IBC have lymph node involvement and 25% have distant metastases upon diagnosis. The signature phenotype of IBC is florid lymphovascular invasion of cancer emboli. Whereas most human xenografts grow as a subcutaneous confluent cellular mass, MARY-X grows exclusively in the murine lymphatic and blood vessels, recapitulating the phenotype displayed in human IBC and in essence providing both a preclinical IBC model and a relevant model of metastasis. MARY-X, in vitro, is a primary cellular derivative from tumor explants. These tumor cells spontaneously form tight, compact aggregates of cells termed “MARY-X spheroids”. Comparable to human IBC emboli, a persistent, over-expression of an intact E-cadherin/α, β-catenin axis mediates the compaction of both in vitro and in vivo MARY-X spheroids and tumor emboli, respectively. The in vitro MARY-X spheroid has comparative 3-dimensional (3-D) architectural/pathophysiological features to the lymphovascular embolus. Therefore MARY-X provides a relevant 3D in vitro analysis platform for drug design and development of IBC and metastatic disease i.e. the lymphovascular embolus.

    Member of:
    American Association for Cancer Research

    Education/Academic qualification

    doctorate, University of Houston


    Fingerprint Dive into the research topics where Mary Alpaugh is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

    • 1 Similar Profiles

    Network Recent external collaboration on country level. Dive into details by clicking on the dots.


    Research Output

    • 1484 Citations
    • 17 h-Index
    • 29 Article
    • 1 Comment/debate
    • 1 Letter
    • 1 Review article
  • 1 Scopus citations

    Paradigms for Precision Medicine in Epichaperome Cancer Therapy

    Alpaugh, M. L., Nov 11 2019, In : Cancer Cell. 36, 5, p. 559-573.e7

    Rowan University

    Research output: Contribution to journalArticle

  • 3 Scopus citations

    Reply to ‘H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines’

    Alpaugh, M. L., Oct 1 2019, In : Nature genetics. 51, 10, p. 1427-1428 2 p.

    Rowan University

    Research output: Contribution to journalLetter

  • 3 Scopus citations
  • 6 Scopus citations

    Press / Media